New Lyme Antibiotics - About Hygromycin A and Azlocillin

Your source for quality supplements

Shop Now

New Lyme Antibiotics - Hygromycin A and Azlocillin Image

Promising Lyme Antibiotics in Development

There are two recent antibiotic discoveries that could change the course of Lyme disease treatment. One of these is Azlocillin and the other is Hygromycin A.

  • Azlocillin is an FDA approved antibiotic shown in laboratory experiments, including mouse experiments, to effectively treat persister phase and growth phase Lyme. You can read more about persisters in How to Treat Persisters in Lyme & Bartonella. There is one hitch—no pharmaceutical company currently produces this medication. This may change in the next couple of years as a company called FlightPath is working to bring this to market. While mouse experiments and other science experiments look promising, we will have to see what human studies eventually show.
  • Hygromycin A is a substance found in soil that targets Lyme spirochetes and does not appear to target other bacteria—so it should not disturb the intestinal microbiome. No experiments to date have been published that determine if it will also treat persister phase Lyme. FlighPath is also developing this novel therapeutic. However, because it is not US Food and Drug Administration (FDA) approved, it could take eight years or more to bring this to market. FlightPath must first perform the required laboratory and clinical studies to get FDA approval.

Lyme Protocol

For current treatment options that may speed your Lyme recovery see The Ross Lyme Support Protocol

Marty Ross MD Discusses Hygromycin A and Azlocillin

 
 
 
Video Thumbnail
 
 
 
 
 
 
 
 
 
 
1:13
 
 
 
 
 
 
 
 
 

 

References

View Citations

  1. Pothineni VR, Potula HSK, Ambati A, et al. Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31. Sci Rep. 2020;10(1):3798. Published 2020 Mar 2. doi:10.1038/s41598-020-59600-4 (View)
  2. Leimer N, Wu X, Imai Y, et al. A selective antibiotic for Lyme disease. Cell. 2021;184(21):5405-5418.e16. doi:10.1016/j.cell.2021.09.011 (View)

See full profile: on LinkedIn 
Follow: on Twitter, YouTube, and Instagram

About the Author

Marty Ross, MD is a passionate Lyme disease educator and clinical expert. He helps Lyme sufferers and their physicians see what really works based on his review of the science and extensive real-world experience. Dr. Ross is licensed to practice medicine in Washington State (License: MD00033296) where he has treated thousands of Lyme disease patients in his Seattle practice. 

Marty Ross, MD is a graduate of Indiana University School of Medicine and Georgetown University Family Medicine Residency. He is a member of the International Lyme and Associated Disease Society (ILADS) and The Institute for Functional Medicine.

keep up with our LATEST!

Join our email list and receive a FREE pdf download book: Antigerm Action Plans for Lyme Disease, 10 email health tips, updates, special offers and more.

© 2022 TREAT LYME